In a research note issued today, H.C.
In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Spectrum Pharmaceuticals (NASDAQ:SPPI) with a …
In a research report issued Friday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Spectrum Pharmaceuticals (NASDAQ:SPPI) with a $15 price target, following …
In a research report issued today, H.C.
In a research note published August 8, Roth Capital analyst Joseph Pantginis issued a note in which he reiterated a Buy rating on Spectrum …
In a research report released August 8, H.C.
